Achieve Life Sciences Inc Total Liabilities

Latest as of March 2026: €22.43 Million EUR ≈ $26.22 Million USD

Achieve Life Sciences Inc total liabilities. Based on the latest financial reports, Achieve Life Sciences Inc (SP4P) has total liabilities worth €22.43 Million EUR (≈ $26.22 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Achieve Life Sciences Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Achieve Life Sciences Inc (2016–2025)

Total liabilities of Achieve Life Sciences Inc from 2016 to 2025. This chart illustrates how Achieve Life Sciences Inc's total liabilities have evolved over time, based on quarterly financial data.

Achieve Life Sciences Inc Competitors by Total Liabilities

The table below lists competitors of Achieve Life Sciences Inc ranked by their total liabilities.

Company Country Total Liabilities
Guangxi Nanning Waterworks Co
SHG:601368
China CN¥21.35 Billion
BES Engineering Co
TW:2515
Taiwan NT$43.56 Billion
Bridgewater Bancshares Inc
NASDAQ:BWB
USA $4.84 Billion
Sparebank 1 Ostfold Akershus
OL:SOAG
Norway Nkr27.30 Billion
SeaBird Exploration Plc
OL:SBX
Norway Nkr20.23 Million
Konka Group Co Ltd
SHE:000016
China CN¥24.50 Billion
Shen Zhen Bauing Construction Holding Group Co Ltd
SHE:002047
China CN¥1.25 Billion
Meridian Mining UK Societas
TO:MNO
Canada CA$2.75 Million

Liability Composition Analysis (2016–2025)

This chart breaks down Achieve Life Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SP4P current and non-current assets.

Liquidity & Leverage Metrics

Achieve Life Sciences Inc Total Liabilities Ratios Explained

Achieve Life Sciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 2.62 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 2.10 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.68 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Achieve Life Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Achieve Life Sciences Inc (2016–2025)

The table below shows the annual total liabilities of Achieve Life Sciences Inc from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 €20.27 Million
≈ $23.70 Million
+14.31%
2024-12-31 €17.73 Million
≈ $20.73 Million
-14.82%
2023-12-31 €20.82 Million
≈ $24.34 Million
-3.92%
2022-12-31 €21.67 Million
≈ $25.33 Million
+11.27%
2021-12-31 €19.47 Million
≈ $22.77 Million
+546.55%
2020-12-31 €3.01 Million
≈ $3.52 Million
-0.53%
2019-12-31 €3.03 Million
≈ $3.54 Million
-7.74%
2018-12-31 €3.28 Million
≈ $3.84 Million
+63.04%
2017-12-31 €2.01 Million
≈ $2.35 Million
-76.33%
2016-12-31 €8.50 Million
≈ $9.94 Million
--

About Achieve Life Sciences Inc

F:SP4P Germany Biotechnology
Market Cap
$726.12 Million
€621.09 Million EUR
Market Cap Rank
#11197 Global
#1292 in Germany
Share Price
€6.05
Change (1 day)
-5.47%
52-Week Range
€2.29 - €7.25
All Time High
€5709.00
About

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more